These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 24002366

  • 1. The effect of somatostatin analogs on vitamin D and calcium concentrations in patients with acromegaly.
    Ajmal A, Haghshenas A, Attarian S, Barake M, Tritos NA, Klibanski A, Miller KK, Nachtigall LB.
    Pituitary; 2014 Aug; 17(4):366-73. PubMed ID: 24002366
    [Abstract] [Full Text] [Related]

  • 2. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM.
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term treatment of acromegaly with lanreotide: evidence of increased serum parathormone concentration.
    Cappelli C, Gandossi E, Agosti B, Cerudelli B, Cumetti D, Castellano M, Pirola I, De Martino E, Rosei EA.
    Endocr J; 2004 Dec; 51(6):517-20. PubMed ID: 15644568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
    Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, Giampietro A, Tartaglione L, Chiloiro S, Appetecchia M, Gargiulo P, Fabbri A, Toscano V, Pontecorvi A, De Marinis L.
    J Exp Clin Cancer Res; 2013 Jun 21; 32(1):40. PubMed ID: 23799893
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A.
    Pituitary; 2007 Jun 21; 10(3):227-32. PubMed ID: 17484056
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K, Fidan M, Çolak R, Durmuş B.
    Growth Horm IGF Res; 2022 Dec 21; 67():101502. PubMed ID: 36115256
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ.
    Eur J Endocrinol; 2009 Apr 21; 160(4):529-33. PubMed ID: 19141604
    [Abstract] [Full Text] [Related]

  • 15. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
    Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ.
    Pituitary; 2011 Sep 21; 14(3):253-8. PubMed ID: 21221818
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
    Reimondo G, Bondanelli M, Ambrosio MR, Grimaldi F, Zaggia B, Zatelli MC, Allasino B, Laino F, Aroasio E, Termine A, Conton P, Paoletta A, Demenis E, Uberti ED, Terzolo M.
    Endocrine; 2014 Feb 21; 45(1):122-7. PubMed ID: 23794116
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
    Zhang L, Wu X, Yan Y, Qian J, Lu Y, Luo C.
    Brain Dev; 2015 Feb 21; 37(2):181-90. PubMed ID: 24815226
    [Abstract] [Full Text] [Related]

  • 19. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep 21; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 20. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
    Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ.
    J Clin Endocrinol Metab; 2008 Oct 21; 93(10):3853-9. PubMed ID: 18647806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.